tiprankstipranks
Trending News
More News >

MAIA Biotechnology Reports Positive Phase 2 Trial Results

Story Highlights
MAIA Biotechnology Reports Positive Phase 2 Trial Results

Don’t Miss TipRanks’ Half-Year Sale

MAIA Biotechnology, Inc. ( (MAIA) ) has issued an update.

On June 5, 2025, MAIA Biotechnology announced positive results from its Phase 2 THIO-101 clinical trial for advanced non-small cell lung cancer (NSCLC), showing a median overall survival of 17.8 months for patients treated with ateganosine (THIO) and Regeneron’s immune checkpoint inhibitor cemiplimab. This outcome is nearly triple the standard-of-care chemotherapy results and indicates a significant potential shift in NSCLC treatment. The company anticipates multiple regulatory pathways for accelerated FDA approval and exclusivity for ateganosine, potentially impacting its market positioning and offering new hope for patients resistant to existing therapies.

The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.

Spark’s Take on MAIA Stock

According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.

MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.

To see Spark’s full report on MAIA stock, click here.

More about MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company’s lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.

Average Trading Volume: 199,853

Technical Sentiment Signal: Sell

Current Market Cap: $53.04M

See more insights into MAIA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1